Top-Analysts PicksInvest alongside the top 15% of Wall Street analysts.

Try Top-Picks
Ginkgo Bioworks Holdings, Inc. Banner

Ginkgo Bioworks Holdings, Inc.

DNA Stock Analysis

Page title

Section title

About Ginkgo Bioworks Holdings, Inc.

Biotechnology
Healthcare

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Ginkgo Bioworks Holdings, Inc. Key Metrics

Market Cap
$465M
52 Weeks Low
$5.26
52 Weeks High
$82.80
P/B
0.52x
P/E
-0.48x
P/S
2.52x

Upcoming Events

    DNA Analyst Forecasts

    ‌
    ‌

    DNA Financials

    DNA Income Statement Key Metrics

    • Revenue(TTM)184.34 M
    • Gross Profit(TTM)108.34 M
    • EBITDA(TTM)-459.73 M
    • Net Income(TTM)-897.68 M
    • EPS Diluted(TTM)-13.75

    Decode DNA's Latest Earnings Call with Ease

    Tap 'Generate' for a crystal-clear,
    AI-crafted summary and stay ahead in the investment game!

    DNA earnings and revenue history

    DNA Return on Equity

    See how efficiently DNA generates profit for it's shareholders.

    0%

    10
    0
    100

    1. Poor

    2. Average

    3. Strong

    Return on Equity Growth

    DNA's Return on Equity has shown poor growth over the past 10 years, increasing by only 0%.

    DNA Revenue Growth

    See how DNA has grown it's revenue over the past 10 years.

    ‌

    Revenue Growth

    DNA's revenue has grown significantly over the past 10 years, increasing by over 16.95%.